ANCA Vasculitis Drug Market, By Type, By Drug Type, By Distribution Channel, By Geography

Description

Anca Vasculitis Drug Market is estimated to be valued at USD 574.9 Mn in 2026 and is expected to reach USD 836.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 574.9 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.50%	2033 Value Projection:	USD 836.3 Mn

Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune diseases characterized by inflammation and damage to small blood vessels. Self-reactive antibodies known as ANCAs, which bind to and excessively activate neutrophils, are the cause behind this inflammation. This immune system malfunction is caused by hereditary and environmental factors. ANCA vasculitis can result in a variety of symptoms depending on the organ or body part affected. For instance, if the skin's blood vessels are harmed, a rash may result. Blood and protein leakage into the urine as well as kidney damage can result from problems with the blood vessels in the kidney. There are three main types of ANCA vasculitis, microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Currently, there is no cure for the disease and treatments are available to manage the condition. Patients normally undergo two phases of treatment, one designed to induce the remission of symptoms (induction treatment), and a second phase meant to keep patients in remission for as long as possible (maintenance treatment).

Market Dynamics

Key players in market are focused on carrying out research and development activities and demonstrating the results of the studies at various medical conferences, which is expected to drive the market growth over the forecast period. For instance, in May 2022, ChemoCentryx, Inc., a biopharmaceutical company, announced upcoming presentations at three key medical conferences that would highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of tavneos (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis. The three conferences were ATS 2022 (American Thoracic Society), May 15-17, 2022, San Francisco, ISPOR 2022 (International Society for Pharmacoeconomics and Outcomes Research), May 15-18, 2022, Washington, and 59th ERA Conference (European Renal Association), May 19-22, 2022, Paris, France/Virtual

Key features of the study

This report provides in-depth analysis of the global ANCA vasculitis drug market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global ANCA vasculitis drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen, InflaRx GmbH, and AstraZeneca
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global ANCA vasculitis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ANCA vasculitis drug market

Market Segmentation

Global ANCA Vasculitis Drug Market, By Type
- Granulomatosis with Polyangiitis (GPA)
- Microscopic Polyangiitis (MPA)
- Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- Renal-limited Vasculitis
Global ANCA Vasculitis Drug Market, By Drug Type
- Glucocorticoids
- Cyclophosphamide
- Rituximab
- Methotrexate
- Mycophenolate mofetil
- Azathioprine
- Mepolizumab
- Avacopan
- Others
Global ANCA Vasculitis Drug Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global ANCA Vasculitis Drug Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Key Players
- ChemoCentryx, Inc.
- Vifor Pharma
- GlaxoSmithKline plc
- Amgen
- Genentech, Inc.
- Pfizer Inc.
- Biogen
- InflaRx GmbH
- AstraZeneca.

Product Code: CMI5154

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Country
  - Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
PEST Analysis
Epidemiology
Product Launch/Approvals

4. Global ANCA Vasculitis Drug Market, By Type, 2026 - 2033, (USD Mn)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Granulomatosis with Polyangiitis (GPA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Microscopic Polyangiitis (MPA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Renal-limited Vasculitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

5. Global ANCA Vasculitis Drug Market, By Drug Type, 2026 - 2033, (USD Mn)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Glucocorticoids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Cyclophosphamide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Rituximab
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Methotrexate
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Mycophenolate mofetil
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Azathioprine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Mepolizumab
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Avacopan
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

6. Global ANCA Vasculitis Drug Market, By Distribution Channel, 2026 - 2033, (USD Mn)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

7. Global ANCA Vasculitis Drug Market, By Region, 2026 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - UK
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

ChemoCentryx, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Vifor Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biogen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
InflaRx GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

9. Section

Research Methodology
About Us